BECHET’S SYNDROME
Bechet’s disease is characterized by:
| A | Hypopyon | |
| B |
Hyphema |
|
| C | Subconjuctival hemmorrhage | |
| D |
Scleritis |
Bechet’s disease is characterized by:
| A | Hypopyon | |
| B |
Hyphema |
|
| C | Subconjuctival hemmorrhage | |
| D |
Scleritis |
Hypopyon REF: Khurana 4th ed p. 156
Uveitis in bechet’s disease
- Bilateral
- Recurrent iridocyclitis
- Hypopyon
- Viteritis
- Periphlebitis
- Retinitis
Bechet’s syndrome is characterized by all of the following eye manifestations, EXCEPT:
| A |
Posterior uveitis |
|
| B |
Iritis |
|
| C |
Optic Neuritis |
|
| D |
Retinal pigmentation |
Bechet’s syndrome is characterized by all of the following eye manifestations, EXCEPT:
| A |
Posterior uveitis |
|
| B |
Iritis |
|
| C |
Optic Neuritis |
|
| D |
Retinal pigmentation |
The eye disease is present in 50% of patients with Bechet’s syndrome. It is usually present at the onset but may also develop within the first few years.
Iritis, posterior uveitis, retinal vessel occlusions and optic neuritis can be seen in some patients with the syndrome.
Note: Scarring and bilateral panuveitis is the most dreaded complication of Bechet’s, since it occasionally progresses rapidly to blindness.
Ref: Moutsopoulos H.M. (2012). Chapter 327. Behçet’s Syndrome. In D.L. Longo, A.S. Fauci, D.L. Kasper, S.L. Hauser, J.L. Jameson, J. Loscalzo (Eds), Harrison’s Principles of Internal Medicine, 18e.
HLA marker of bechet’s syndrome
| A |
HLA-B27 |
|
| B |
HLA-DR5 |
|
| C |
HLA-B51 |
|
| D |
HLA-CW6 |
HLA marker of bechet’s syndrome
| A |
HLA-B27 |
|
| B |
HLA-DR5 |
|
| C |
HLA-B51 |
|
| D |
HLA-CW6 |
Ans. is ‘c’ i.e., HLA-B51
A patient gives hi° recurrent oral ulcers. The ulcers are small with a yellow floor surrounded by an erythematous halo on lips. He also has multiple, tender nodules on shin. The probable diagnosis is
| A |
Pemphigus vulgaris |
|
| B |
Bechet’s syndrome |
|
| C |
Herpes Labialis |
|
| D |
Fixed drug eruption |
A patient gives hi° recurrent oral ulcers. The ulcers are small with a yellow floor surrounded by an erythematous halo on lips. He also has multiple, tender nodules on shin. The probable diagnosis is
| A |
Pemphigus vulgaris |
|
| B |
Bechet’s syndrome |
|
| C |
Herpes Labialis |
|
| D |
Fixed drug eruption |
B i.e. Bechet’s syndrome
Recurrent oral apthous ulcers (oral ulcers with yellow floor surrounded by erythematous halo) with erythema nodosum like nodules (multiple, tender nodules on shin) suggest the diagnois of Behcet’s syndrome.
Recurrent orogenital ulceration with arthritis is seen in
| A |
Bechets syndrome |
|
| B |
Gonorrhoea |
|
| C |
Reiters syndrome |
|
| D |
a and c |
Recurrent orogenital ulceration with arthritis is seen in
| A |
Bechets syndrome |
|
| B |
Gonorrhoea |
|
| C |
Reiters syndrome |
|
| D |
a and c |
A i.e. Becht’s syndrome, C. i.e. Reiter’s syndrome
Reiter’s syndrome (reactive arthritis) is an acute nonpurulent, asymmetrical, additive (poly) arthritis triggered by an infection elsewhere (like STD, enteric infection because of travel to endemic area), HIV & HLA B 27Q. It presents with classical triad of “CUP” i.e. conjunctivitis, urethritis and polyarthritis Q. Dactylitis (sausage digit), enthesitis, asymmetrical spondylitis & sacroilitis, onycholysis & hyperkeratosis of nails, circinate balanitis of glans, keratodernia blenorrhagica on palms & soles and superficial asymptomatic aoral ulcers are other features of reactive arthritis.
Thalidomide is not used in
| A |
ENL |
|
| B |
Bechet’s syndrome |
|
| C |
HIV associated Oral ulcers |
|
| D |
HIV associated neuropathy |
Thalidomide is not used in
| A |
ENL |
|
| B |
Bechet’s syndrome |
|
| C |
HIV associated Oral ulcers |
|
| D |
HIV associated neuropathy |
D i.e. HIV associated neuropathy
Peripheral neuropathy is a dose limiting toxicity of thalidomide & not a therapeutic indicationQ. It causes painful sensory ganglionopathy & axonal neuropathy.
Indications of Thalidomide
– Erythema nodosum leprosum (ENL)Q: Only FDA approved use for treatment of cutaneous manifestations . of moderate to severe ENL and for maintenance therapy for prevention and suppression of cutaneous manifestations of ENL recurrence.
– Severe, recurrent apthous stomatitisQ, especially in AIDS patients is common off label use. – Behects syndromeQ
– Chronic graft versus host disease.
* HIV associated colitis and wasting, multiple myeloma, myelodysplasia, chronic idiopathic myelofibrosis, glucocorticosteroid refractory fistulosis-Chron’s disease, sarcoidosis, prurigo, stomatitis are other rare uses.
Pathergy test is used for ‑
| A |
Reither’s syndrome |
|
| B |
Bechet’s syndrome |
|
| C |
Lichen planus |
|
| D |
Atopic dermatitis |
Pathergy test is used for ‑
| A |
Reither’s syndrome |
|
| B |
Bechet’s syndrome |
|
| C |
Lichen planus |
|
| D |
Atopic dermatitis |
Ans. is ‘b’ i.e., Bechet’s syndrome
Criteria for diagnosis of Bechet’s disease
- Recurrent oral ulcer for at least 3 times in 12 months.
- Plus any two of the followings :‑
- Recurrent genital ulcer.
- Eye inflammation with loss of vision.
- Characterstic skin lesion (erythema nodosum).
- Positive pathergy test (skin prick test).
HLA marker of bechet’s syndrome ‑
| A |
HLA-B27 |
|
| B |
HLA-DR5 |
|
| C |
HLA-B51 |
|
| D |
HLA-CW6 |
HLA marker of bechet’s syndrome ‑
| A |
HLA-B27 |
|
| B |
HLA-DR5 |
|
| C |
HLA-B51 |
|
| D |
HLA-CW6 |
Ans. is ‘c’ i.e., HLA-B51



